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Unfortunately, mutations in this gene can also lower the sensitivity of radiolabeled metaiodobenzylguanidine (MIBG). MIBG scanning is considered the gold standard imaging modality for the diagnosis of recurrent disease but this case illustrates the potential diagnostic pitfalls associated with this imaging modality in cases of SDHB gene mutations. The case demonstrates the importance of genotyping as a diagnostic and predictive tool and the importance of clinical acumen in the face of negative test results.
Background
This gentleman underwent a MRI of pelvis in February 2011 for investigation of possible sacroiliitis on a background of known inflammatory bowel disease. This MRI demonstrated a 2.3 Â 2.3 cm nodule posterior to the pubic symphysis in close proximity to the prostate. The patient underwent two ultrasound guided biopsies of the nodule but histology was inconclusive. The nodule was excised in July 2011 and intraoperatively the patient had a hypertensive crisis and urinary catecholamines and metanephrines were performed. Urinary metanephrines levels were elevated and patient was subsequently referred to the endocrine service. The patient denied any symptoms of anxiety, headaches, palpitations, weight loss or sweating. He had no history of hypertension and the only medical history of note was ulcerative colitis which was quiescent. The only symptom reported was left hip pain. He had no relevant family history. On examination the patient had no cutaneous or syndromic features but did have low grade hypertension.
2. Urine collection for metanephrines and caetacholamines.
Analysis performed using high-performance liquid chromatography. 3. Genetic analysis Genetic analysis was performed in the West Midlands regional genetic laboratory, UK.
Heterozygous pathological deletion of exon 3 on the SDHB gene identified.
4. Radiology 18FDG positron emission topography (PET) CT scan revealed lytic lesions within the left petrous apex, left humeral head and mid right femoral diaphysis, which also showed increased uptake of 18FDG FDG and findings suggested skeletal metastases. There was avid uptake of radiopharmaceutical within these lesions on 131MIBG
imaging. An area of lucency was noted in the left proximal femur on MRI Figure 1 (a) and plain film. On MIBG scanning, there was no increased uptake Figure 1 (b) of radiopharmaceutical within the lytic lesion.
Histology
(1) Histology of resected extra prostatic nodule showed a nested tumour which was strongly positive with the neuroendocrine markers chromogranin A and synaptophysin, in keeping with metastatic paraganglioma.
(2) Biopsy of the left femur showed multiple fragments of bone, fibro-connective tissue, haemorrhage and fibrosis which demonstrated both chromogranin and synaptophysin staining. The morphological and immunohistochemical findings were consistent with necrotic neuroendocrine tumour.
Discussion
Anatomical localization of phaeochromocytmas (PHEO) and paragangliomas (PGLs) is often confirmed by CT or MRI after a biochemical diagnosis. However, functional imaging remains the gold There is also a focus of increased uptake in the right suprarenal area and left petrous apex at skull base (arrows). There is no abnormal uptake within the left femoral diaphysis.
standard and practices have shifted in recent years with the discovery of specific genotype-phenotype correlations. 2 MIBG remains the first line nuclear imaging modality and is essential in the diagnosis and work up for I 131MIBG therapy. I 131MIBG conveys function of the tumour. The sensitivity of I 131MIBG is reduced in patients with SDHB mutations and in dopamine secreting tumours. 3 The suboptimal sensitivity of I 131I MIBG for metastatic PHEO and PGL has been reported in studies and attributed to the de-differentiation of tissue that results in loss of norepinephrine transporters in the tumour. 4 PET combined with radiolabeled somatostatin analogues has shown a high sensitivity for the detection of small tumours and particularly in the detection of metastatic disease involving lung and bone. 5 In cases of metastatic PGLs or hereditary PGLs secondary to SDHB mutation, the superior nuclear imaging modality is 18F-FDG PET. 6 In this case, we present the findings of a metastatic paraganglioma with metastatic deposits to the femur, in which there was no increased uptake of 18 FDG on PET or I 131MIBG. There are two possible hypotheses for the lowered sensitivity of functional imaging in this case. One explanation is that the areas of necrosis noted on histology interfered with the uptake of FDG and MIBG. The second possibility is that the genetic defect in SDHB caused a de-differentiation of the metastatic deposit. This case highlights the complex nature of this neuroendocrine tumour and the diagnostic dilemma faced due to the atypical behaviour of metastatic lesions on scintigraphy.
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